Precosa Neutral: Uses, Dosage & Side Effects

What Is Precosa Neutral and What Is It Used For?

Precosa Neutral belongs to the class of antidiarrheal microorganisms (ATC code A07FA02). Unlike most medicines, the active ingredient is not a chemical compound but a living biotherapeutic agent: the yeast Saccharomyces boulardii CNCM I-745. This specific strain was first isolated in the 1920s by the French microbiologist Henri Boulard from the skins of lychee and mangosteen fruits in Indochina, where he observed local populations using the fruits as a traditional remedy for cholera-associated diarrhea. The strain has been developed into a pharmaceutical preparation that has been used clinically for more than seven decades and is now registered as a medicine in many countries worldwide.

The “Neutral” suffix in the product name refers to the flavor profile: Precosa Neutral contains no added flavoring, sweeteners (other than minimal lactose), or coloring. This makes the formulation suitable for patients who cannot tolerate the standard citrus-flavored variant, for patients with fructose intolerance or allergies to flavorings, and for parents who prefer to mix the powder into a small portion of their child's usual food or drink without altering the taste. The active substance, quantity of viable yeast cells, and pharmacological properties are identical to the flavored version.

Precosa Neutral is used for the following clinical indications, with the strength of evidence varying by indication:

• Prevention of antibiotic-associated diarrhea (AAD): The best-studied indication. Multiple systematic reviews and meta-analyses of randomized controlled trials show that S. boulardii co-administered with antibiotics reduces the incidence of AAD by approximately 50% in both adults and children.
• Prevention of recurrence of Clostridioides difficile infection (CDI): When added to standard antibiotic therapy (vancomycin or fidaxomicin) for recurrent CDI, S. boulardii has been shown to reduce the risk of further recurrences in adult patients.
• Acute infectious diarrhea in children: The European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) recommends that S. boulardii may be considered as an adjunct to oral rehydration in children with acute gastroenteritis, with evidence showing reduction in stool frequency and duration of diarrhea by approximately 24–48 hours.
• Traveler's diarrhea: Used preventively by travelers visiting high-risk destinations. Evidence is moderate; the product is started a few days before travel and continued throughout the trip.
• Adjunct in Helicobacter pylori eradication therapy: When added to triple or quadruple therapy, S. boulardii may improve eradication rates and reduce gastrointestinal side effects of the antibiotic regimen.
• Functional gastrointestinal disorders: Some studies suggest a role in irritable bowel syndrome (IBS) with diarrhea and in inflammatory bowel disease in remission, though evidence is less robust and use in these indications may be off-label.

Mechanistically, S. boulardii CNCM I-745 exerts its therapeutic effects through several distinct, non-redundant pathways. It produces proteases (notably a 54 kDa protease) that cleave and inactivate C. difficile toxins A and B, the major virulence factors in pseudomembranous colitis. It binds to the cell-surface receptors of various enteropathogens (including Escherichia coli, Vibrio cholerae, and Salmonella typhimurium), reducing their ability to adhere to and invade the intestinal mucosa. It stimulates the production of secretory immunoglobulin A (sIgA) and modulates mucosal immune responses, including down-regulation of pro-inflammatory cytokines and up-regulation of anti-inflammatory mediators. It enhances the activity of intestinal disaccharidases (lactase, sucrase, maltase), which can be transiently depleted during acute diarrhea. Finally, it helps preserve and restore the normal composition of the intestinal microbiota during antibiotic exposure or infectious insult.

Importantly, S. boulardii does not permanently colonize the human gastrointestinal tract. Following oral administration, viable yeast cells reach the small intestine and colon, where they exert their local effects, and are then cleared from the gut within 3 to 5 days after discontinuation. This pharmacokinetic profile means that for continuous prophylaxis (for example, during a 10-day antibiotic course), the product must be taken throughout the course and for several days afterward. It also means that S. boulardii is intrinsically self-limiting and does not establish a permanent niche in the host.

What Should You Know Before Taking Precosa Neutral?

Contraindications

Although Saccharomyces boulardii has an excellent overall safety record in healthy individuals, specific patient populations must not use Precosa Neutral because of a rare but potentially life-threatening risk of fungemia (yeast bloodstream infection). Understanding these absolute contraindications is essential for safe use.

• Critically ill patients: Precosa Neutral must not be used in patients who are critically ill, including those in intensive care units, patients with severe sepsis, and patients with extensive burns or major trauma. In such patients, the intestinal barrier may be compromised, increasing the risk of yeast translocation into the bloodstream.
• Severely immunocompromised patients: Patients with advanced HIV/AIDS, hematological malignancies, active solid organ cancers receiving chemotherapy, solid organ or hematopoietic stem cell transplant recipients, and patients on high-dose immunosuppressive therapy must not take Precosa Neutral due to reduced ability to contain opportunistic infections.
• Central venous catheter (CVC): Patients with any form of central venous catheter (including peripherally inserted central catheters [PICC lines], tunneled catheters, and implanted ports) must not take Precosa Neutral. Airborne dissemination of yeast during sachet opening has been associated with catheter colonization and subsequent fungemia, even in patients who did not themselves receive the product.
• Hypersensitivity: Do not use Precosa Neutral in patients with a known allergy to Saccharomyces boulardii, other yeasts, or any of the inactive ingredients (including lactose).
• Premature infants: Safety in preterm neonates has not been established, and there are published case reports of fungemia in this population. Precosa Neutral should not be used in premature or very young infants unless specifically recommended by a specialist.

Warnings and Precautions

Before starting Precosa Neutral, inform your doctor or pharmacist if any of the following apply to you:

• Lactose intolerance: Precosa Neutral contains lactose as an excipient. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medicine. Most patients with common lactose intolerance tolerate the small amount of lactose in a single sachet, but discuss with your doctor if unsure.
• Severe underlying disease: Patients with severe underlying gastrointestinal disease (such as severe inflammatory bowel disease with mucosal breakdown) should only use Precosa Neutral under medical supervision.
• Persistent or bloody diarrhea: If you have high fever, blood in the stools, severe abdominal pain, or signs of dehydration, do not self-treat with Precosa Neutral alone. These symptoms may indicate invasive infection or another serious condition requiring urgent medical assessment. Always seek medical advice for diarrhea lasting more than 2 days in adults or more than 24 hours in infants and young children.
• Oral rehydration: Precosa Neutral is not a substitute for fluid and electrolyte replacement. In acute diarrhea, particularly in children and the elderly, maintaining adequate hydration with oral rehydration solution (ORS) is the cornerstone of treatment. Probiotics are adjunctive therapy only.
• Surgical procedures: If you are scheduled for major surgery, particularly gastrointestinal surgery, inform the surgical team that you are taking Precosa Neutral. It may be advisable to stop the product prior to surgery.

Pregnancy and Breastfeeding

Clinical data on the use of Saccharomyces boulardii during pregnancy are limited. Animal reproduction studies have not demonstrated teratogenic or embryotoxic effects, and observational data in pregnant women have not revealed a clear increase in risk. However, due to the absence of large, well-controlled studies, Precosa Neutral should only be used during pregnancy when clearly necessary and after an individual risk-benefit assessment by a healthcare professional. The potential benefit in preventing antibiotic-associated diarrhea in a pregnant woman receiving antibiotics for a significant infection generally outweighs the theoretical risks.

S. boulardii is administered orally, exerts its effects locally in the intestine, and is not absorbed systemically into the bloodstream. It is therefore not expected to be present in breast milk in pharmacologically relevant amounts. Formal studies in breastfeeding women are lacking. Breastfeeding mothers who are prescribed Precosa Neutral should discuss the use with their healthcare provider, but the product is generally considered compatible with breastfeeding when clinically indicated.

Driving and Operating Machinery

Precosa Neutral has no known effect on the ability to drive, operate machinery, or perform cognitive tasks. The active ingredient is not absorbed systemically and does not cross the blood-brain barrier. No central nervous system effects have been reported in clinical trials or post-marketing surveillance.

How Does Precosa Neutral Interact with Other Drugs?

One of the key therapeutic advantages of Saccharomyces boulardii is that, as a yeast, it is intrinsically resistant to virtually all antibacterial antibiotics. This allows Precosa Neutral to be co-administered with antibiotic therapy without being inactivated, which is the basis for its primary indication (prevention of antibiotic-associated diarrhea). However, some clinically relevant interactions do exist, particularly with antifungal agents.

Major Interactions

Minor Interactions and Non-Interactions

What Is the Correct Dosage of Precosa Neutral?

Dosing of Precosa Neutral is guided by patient age, the specific clinical indication, and local prescribing recommendations. The recommendations below reflect international guidance including the EMA Summary of Product Characteristics, ESPGHAN guidelines for pediatric use, and the ACG clinical guidelines for C. difficile management. Always confirm the exact dose and duration with your doctor or pharmacist.

Adults and Adolescents (12 Years and Older)

Children

Pediatric dosing of S. boulardii is supported by ESPGHAN guidelines for the management of acute gastroenteritis in children. The guideline states that S. boulardii may be considered (as an option, not mandatory) alongside oral rehydration solution in children with acute gastroenteritis, based on moderate-quality evidence that it reduces the duration of diarrhea by approximately one day and decreases stool frequency. Probiotics are not a substitute for appropriate fluid and electrolyte replacement, which remains the cornerstone of treatment for childhood diarrhea.

Elderly Patients

No specific dose adjustment is required for older adults based on age alone. However, elderly patients are at higher risk of Clostridioides difficile infection, particularly when exposed to antibiotics, and they may benefit particularly from probiotic prophylaxis. At the same time, older adults more often have comorbidities (such as malignancy, advanced organ dysfunction, or central venous catheters) that may make Precosa Neutral inappropriate. An individual risk-benefit assessment is especially important in this population.

Missed Dose

If you miss a dose of Precosa Neutral, take it as soon as you remember. If it is close to the time for your next dose, simply skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to compensate for a missed one. Because S. boulardii is cleared from the gut relatively quickly, consistent daily dosing is important for continuous preventive effect; however, missing one or two doses is not medically dangerous.

Overdose

There are no reports of serious overdose with Saccharomyces boulardii in healthy individuals. Even substantial ingestion (multiple sachets) is generally expected to cause only mild, self-limiting gastrointestinal symptoms such as flatulence, bloating, and transient diarrhea. There is no specific antidote. Treatment is supportive, with attention to hydration. In immunocompromised individuals, clinicians should be aware of the potential (though low) risk of fungemia following massive ingestion or repeated dosing, and appropriate fungal blood cultures should be considered if systemic illness develops.

What Are the Side Effects of Precosa Neutral?

Across clinical trials and decades of post-marketing surveillance, Saccharomyces boulardii CNCM I-745 has demonstrated a favorable safety profile in the general population. Most reported adverse events are mild and transient. Serious events are rare and predominantly occur in specific high-risk patient groups identified in the contraindications section. The frequency categories below are based on EMA standards.

Reports of Saccharomyces fungemia in the published literature are overwhelmingly concentrated in hospitalized patients with multiple risk factors, and most have occurred in intensive care settings. Fungemia in otherwise healthy outpatients taking Precosa Neutral is extraordinarily rare. Nonetheless, the small but real risk is the basis for the strict contraindications in critically ill and immunocompromised patients and for careful handling precautions in hospital environments.

If you experience any adverse effects while taking Precosa Neutral, even if they are not listed here, you can report them to your national pharmacovigilance authority (e.g., the MHRA Yellow Card scheme in the UK, the FDA MedWatch program in the US, or the EMA EudraVigilance system in Europe). Reporting helps monitor the ongoing safety of medicines.

How Should You Store Precosa Neutral?

Because Precosa Neutral contains live, lyophilized (freeze-dried) yeast cells, proper storage is essential to maintain the viability of the active ingredient. Improper storage — particularly exposure to heat or moisture — can reduce or eliminate the number of viable cells in a sachet, rendering the product ineffective even before its printed expiry date.

• Temperature: Store at room temperature, below 25°C (77°F). Avoid storage in bathrooms, near radiators, in direct sunlight, or in glove compartments of vehicles where temperatures can exceed 40°C. Refrigeration is not required for unopened sachets.
• Humidity: Keep sachets in a dry place in their original packaging. Do not remove sachets from the outer box until you are ready to use them. The foil-lined sachet itself is the primary moisture barrier.
• Do not freeze: While low temperatures generally preserve yeast viability, repeated freeze-thaw cycles can damage the cells. Do not store in the freezer.
• Once opened: A sachet should be used immediately after opening. Do not save partially used sachets for later use.
• Prepared suspension: Once the contents have been mixed with water, milk, juice, or food, consume within a few minutes. Do not store the prepared mixture for later use, as yeast viability declines and unwanted microbial growth can occur.
• Child safety: Keep all medicines out of the sight and reach of children. Although accidental ingestion of Precosa Neutral is generally not dangerous to a healthy child, medicines should always be stored securely.
• Disposal: Do not dispose of Precosa Neutral in household waste or down the drain. Return any unused or expired sachets to your local pharmacy for safe disposal in accordance with national pharmaceutical waste regulations.

Do not use Precosa Neutral after the expiry date (“EXP”) printed on the sachet and the outer carton. The expiry date refers to the last day of the stated month. Expired sachets may contain insufficient viable yeast cells to be effective and should be returned for disposal.

What Does Precosa Neutral Contain?

Active Substance

Each sachet contains 250 mg of Saccharomyces boulardii CNCM I-745 as lyophilized (freeze-dried) powder. “CNCM I-745” is the official strain designation assigned by the Collection Nationale de Cultures de Microorganismes at the Institut Pasteur in Paris, where the reference strain is deposited. This specific strain identifier is important because different S. boulardii strains may have different clinical effects, and the published evidence base for Precosa refers specifically to the CNCM I-745 strain.

The lyophilized powder contains metabolically inactive (dormant) yeast cells that become metabolically active once rehydrated in the gut. A typical 250 mg sachet provides on the order of 5 × 10⁹ (5 billion) colony-forming units (CFU) of viable yeast, although the exact CFU count is specified by the manufacturer and may vary slightly between manufacturing batches within an acceptable range.

Inactive Ingredients (Excipients)

The inactive ingredients serve as fillers, stabilizers, and lubricants in the formulation. The typical composition of Precosa Neutral includes:

• Lactose monohydrate: Bulking agent and cryoprotectant (protects yeast cells during freeze-drying). Patients with rare hereditary galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption must not use this product.
• Fructose: Used as a bulking agent and mild sweetener. Patients with hereditary fructose intolerance should not use Precosa Neutral.
• Magnesium stearate: A lubricant used in powder manufacturing.

Unlike the citrus-flavored variant of Precosa, Precosa Neutral does not contain added flavoring agents, artificial sweeteners (such as aspartame), or colorants. This makes it a suitable option for patients with sensitivities to flavoring compounds or who prefer to mix the powder into their own food or drink. Always check the patient information leaflet (PIL) of the specific product you are using for the exact list of excipients, as formulations may be updated by the manufacturer.

Product Appearance

Precosa Neutral is presented as a fine, off-white to pale beige powder packaged in individual single-dose sachets. The sachets are typically supplied in cardboard cartons of varying pack sizes (for example, 10, 20, or 50 sachets). The powder should be free-flowing; if it appears clumped, discolored, or has an unusual odor, do not use it and consult your pharmacist.